IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)
NCT 06112314 Brief Summary This is a phase 3, randomized, controlled study…
Read more arrow_forwardNCT 06112314 Brief Summary This is a phase 3, randomized, controlled study…
Read more arrow_forwardNCT 04291885 Brief Summary The I-MAT trial is a randomised, placebo-controlled, phase…
Read more arrow_forwardNCT 03959085 Brief Summary This phase III trial studies whether inotuzumab ozogamicin…
Read more arrow_forwardNCT 04643002 Brief Summary The purpose of this umbrella study is to…
Read more arrow_forwardNCT 06127407 Brief Summary Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind,…
Read more arrow_forwardNCT 06501625 Brief Summary The objective of this study is to investigate…
Read more arrow_forwardNCT 03662126 Brief Summary This study evaluates KRT-232, a novel oral small…
Read more arrow_forwardNCT 05872295 Brief Summary This study will evaluate the recommended dose for…
Read more arrow_forwardNCT 03486873 Brief Summary The purpose of this study is to…
Read more arrow_forwardNCT 05560659 Brief Summary The aim of this study is to assess…
Read more arrow_forward